

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108
UNITED STATES

Physician: Test, Test

Patient: Testpatient, John

DOB: 8/8/1977
Sex: Male
Patient Identifiers: 66016
Visit Number (FIN): 66429
Collection Date: 12/3/2024 06:33

Prostate-Specific Kallikrein, 4Kscore

ARUP test code 2014059

4K - Biopsy History

NO BIOPSY
Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407
James Weisberger, M.D.,

4K - Digital Rectal Exam (DRE)

NODULE
Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407
James Weisberger, M.D.,

4K - Score

1.8
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

NOTE: Biotin supplementation (>5 mg/day) may cause interference with assays that are components of the 4Kscore Test, and may impact the 4Kscore result.

PROBABILITY OF AGGRESSIVE PROSTATE CANCER BY 4Kscore RANGES

The probability of having aggressive prostate cancer in all African Americans and Non-African Americans by 4Kscore ranges is summarized in the table below:

4KScore Range	% Probability	95% CI
<5.0	4.1%	2.1%, 7.9%
5.0 to <10.0	9.6%	5.8%, 15.5%
10.0 to <20.0	19.7%	14.8%, 25.8%
> or = 20.0	49.4%	44.5%, 54.3%

REFERENCES:
The 4Kscore Test Package Insert;Version 1.0 OPKO Health, Inc.
Digital Rectal Exam (DRE): NO NODULE
Prior Biopsy Status: NO PRIOR BIOPSY
Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407
James Weisberger, M.D.,

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Testpatient, John
ARUP Accession: 24-338-100491
Patient Identifiers: 66016
Visit Number (FIN): 66429
Page 1 of 3 | Printed: 12/3/2024 9:24:02 AM

4K - PSA, Total

3.00 ng/mL (Ref Interval: <4.00)

NOTE: NCCN Guidelines(2.2021)recommend repeat testing every 2-4 years if PSA is <1 ng/mL and every 1-2 years if PSA is 1-3 ng/mL in men aged 45 to 75 years. A PSA value of 1.00 ng/mL selects for the upper range of PSA values. Men who have a PSA above the median for their age group are at a higher risk for prostate cancer and for the aggressive form of the disease. The higher above the median, the greater the risk.

NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be based solely upon values obtained from serial PSA values obtained on the patient.

NOTE: Values obtained with different assay methods or kits cannot be used interchangeably.

NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics)

NOTE: This assay has no biotin interference in serum concentrations up to 1200 ng/mL. Pharmacokinetic studies have shown that serum concentrations of biotin can reach up to 355 ng/mL within the first hour after biotin ingestion for subjects consuming supplements of 20 mg biotin per day and up to 1160 ng/mL for subjects after a single dose of 300 mg biotin.

Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407

James Weisberger, M.D.,

4K - PSA, Free

1.83 ng/mL (Ref Interval: Not Estab.)

NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably.

ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).

NOTE: This assay has no biotin interference in serum concentrations up to 1200 ng/mL. Pharmacokinetic studies have shown that serum concentrations of biotin can reach up to 355 ng/mL within the first hour after biotin ingestion for subjects consuming supplements of 20 mg biotin per day and up to 1160 ng/mL for subjects after a single dose of 300 mg biotin.

Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407

James Weisberger, M.D.,

4K - PSA, Percent Free

61 % (Ref Interval: See Below)

FREE PSA RISK ASSESSMENT

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Testpatient, John
ARUP Accession: 24-338-100491
Patient Identifiers: 66016
Visit Number (FIN): 66429
Page 2 of 3 | Printed: 12/3/2024 9:24:02 AM

The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below:

PROBABILITY OF CANCER*

%free PSA	(50-59 yrs)	(60-69 yrs)	(>or=70 yrs)
<or=10	49.2%	57.5%	64.5%
11-18	26.9%	33.9%	40.8%
19-25	18.3%	23.9%	29.7%
>25	9.1%	12.2%	15.8%

*probability of finding prostate cancer by needle biopsy

NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E602 immunoassay system.(8/2015;v8.0)
Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407

James Weisberger, M.D.,

4K - Clinical Indication for Order

45-54YO+PSA>=2
Performed by: BioReference Health, LLC
481 Edward H. Ross Dr
Elmwood Park, NJ 07407
James Weisberger, M.D.,

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
4K - Biopsy History	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM
4K - Digital Rectal Exam (DRE)	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM
4K - Score	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM
4K - PSA, Total	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM
4K - PSA, Free	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM
4K - PSA, Percent Free	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM
4K - Clinical Indication for Order	24-338-100491	12/3/2024 6:33:00 AM	12/3/2024 6:37:57 AM	12/3/2024 8:39:00 AM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Testpatient, John
ARUP Accession: 24-338-100491
Patient Identifiers: 66016
Visit Number (FIN): 66429
Page 3 of 3 | Printed: 12/3/2024 9:24:02 AM